Bob Leibenluft's antitrust practice focuses on health care and life sciences – yet it spans all industry sectors, including providers, payers, and drug and device manufacturers. He brings over 35 years of experience, including heading the Federal Trade Commission health care division, to his representation of clients in counseling, investigations, transactions, and litigation matters.
On a pro bono basis, Bob has led a 10 year review of the Washington, D.C. government's response to HIV/AIDs, advised the government of Liberia on a new public health law, and provided antitrust advice to the CEO Roundtable on Cancer.
Bob is an inaugural fellow and former vice president of the American Health Lawyers Association. He is a former Chair of the ABA Antitrust Section's Health and Pharmaceuticals Committee, Joint Conduct Committee, and State Enforcement Committee. Bob also served as chair of the board of directors of HCI3, the parent of Prometheus Payment, and Bridges-to-Excellence. He teaches the course Antitrust in the Health Care Sector at George Washington School of Law, where he is an adjunct professor.